Since HGF expression by the tumor itself or by its microenvironment may be required for full activation of MET variants having an N‐lobe mutation in HPRCC, HGF expression could be a valuable biomarker in this cancer. The gene discussed is MET; the disease is papillary renal cell carcinoma.